Biotech Co.* | Pharma Co. (Country) | Type/Product Area | Disclosed Funding (M) | Terms/Details (Date) |
| ||||
Accelrys | GlaxoSmith- | Collaboration to produce software that enables GSK scientists to access, analyze and visualize chemical and biological data | ND | The data are stored on Glaxo's research and development databases (10/25) |
| ||||
Advanced | Medtronic Inc. | Collaboration to explore how the companies' technologies can work together | $20 | A Medtronic affiliate purchased $20M of common stock as part of the partnership; ATS and Medtronic will test ATS's technology in cardiovascular, neurological, endocrinological and spinal areas; Medtronic receives a right of first refusal to develop products and to pursue programs (10/4) |
| ||||
Arakis Ltd. | Penwest | Three-year alliance to develop up to six orally delivered performance- enhanced medicines for the treatment of pain conditions | ND | The new products will be jointly developed in the clinic during the alliance and will be created by combining Penwest's oral drug delivery capability with Arakis' ability to enhance known pharmacological agents (11/14) |
| ||||
Array | Takeda | Agreement to develop small-molecule drug leads | ND | Array could receive milestones, and royalties based on the sales of products from the collaboration (9/20) |
| ||||
Atrix Lab- | Fujisawa | Licensing agreement for North American rights to Atrix's topical acne treatment, Atrisone | $25 | Fujisawa will pay Atrix up to $25M in license fees, research and development support and milestone payments; Atrix will manufacture Atrisone and will receive a manufacturing margin, as well as royalties (10/17) |
| ||||
Atugen AG | AstraZeneca | One-year collaboration to use Atugen's GeneBloc technology to increase efficiency of target validation and drug development in a number of major disease areas | ND | Atugen will retain all rights to Gene-Blocs developed and will have an option to license intellectual property generated (10/16) |
| ||||
Avant Immun- | DynPort | License agreement giving DynPort Vaccine exclusive rights to use certain components of Avant's vaccine technology | ND | DynPort will advance the development of vaccines and other products for the government to protect against biological warfare agents; Avant is entitled to license fees, milestones and royalties (10/10) |
| ||||
BioLeads | Schering AG | Research and license agreement related to potential drug compounds derived from microbial strains | ND | BioLeads plans to provide pre-purified subfractions from microbial strains and perform research to find compounds; BioLeads also granted Schering an exclusive license to use such compounds to develop, produce and market drug products (9/26**) |
| ||||
Bioreason | Warner- | Licensing agreement for Bioreason's software systems | ND | The software, DataPharmer, LeadPharmer and DrugPharmer, is designed to analyze data from high-throughput screening for drug discovery (9/21) |
| ||||
BioVex Ltd. | AstraZeneca | Collaboration in the area of gene target validation | ND | AstraZeneca will evaluate the ability of BioVex's NeuroVEX vectors to efficiently transduce the cells and tissues of the nervous system in order to study the function of genes that may be viable targets for the therapy of neurodegenerative disorders (10/15) |
| ||||
Cambridge | Merck & Co. | Five-year collaboration and license agreement for development of products for a target involved in HIV | ND | Merck will provide HIV biology work and CAT will provide its human phage antibody libraries; Merck gains exclusive rights to resulting products; CAT will receive an up-front technology access fee, milestones and potential royalties on the sale of products (10/10) |
| ||||
Cellomics | Wyeth-Ayerst | Agreement to supply Cellomics' ArrayScan HCS technology | ND | Wyeth-Ayerst will use the technology in its research (11/14) |
| ||||
Ciphergen | Pfizer Inc. | Agreement to discover proteins in serum from rat models | ND | Agreement is also to evaluate the importance of such proteins as biomarkers associated with drug safety (10/8) |
| ||||
CombiMatrix | Marubeni | Joint venture focused on development and licensing opportunities for CombiMatrix's biochip technology | ND | The venture will focus on marketing and developing the technology for the Japanese market; Marubeni provided the funding for the operations and management team by acquiring a minority interest in the joint venture (10/29) |
| ||||
Corixa Corp. | Amersham | Bexxar | $25 | Amersham Health will market Bexxar in Europe; the agreement calls for as much as $15M of Corixa stock to be purchased by Amersham, and an option for another $10M to be sold in the future at times chosen by Corixa (10/29) |
| ||||
CTI Tech- | Chugai Pharma- | Licensing agreement for development and commercialization rights to PG-TXL in several Asian markets, including China, Malaysia, the Philippines and other countries | $73 | CTI will get an up-front payment of $3M and milestone payments totaling $16M; another $54M will be paid by Chugai for development-related expenses (10/22) |
| ||||
Cytos Bio- | Novartis | Research and license option agreements to develop therapeutic vaccines for allergy, rheumatoid arthritis and chronic nervous system disorders | CHF70 | If the option is exercised, Cytos will receive research funding and precommercialization milestone payments of up to US$42.25M, as well as sales royalties (10/23) |
| ||||
De Novo | Roche Diag- | Technology development collaboration in the area of de novo drug design | ND | De Novo will retain full commercial rights of the design platform, Skelgen II; Roche will receive certain rights to use Skelgen II in drug discovery (10/16) |
| ||||
Dendreon | Bayer Corp. | Agreements to license two tumor antigens for use in Dendreon's therapeutic cancer vaccines | ND | The antigens are carcinoembryonic antigen and MN antigen (9/26) |
| ||||
Discovery | Merck & Co. | Multiyear agreement to design, develop and produce libraries of drug-like high-purity chemical compounds | ND | Discovery Partners will collaborate with Merck to develop custom compound libraries, then will manufacture and purify the compound using its high-speed purification technology (10/23) |
| ||||
DNA Sciences | Bristol-Myers | Partnership to investigate genetic variants within a potential gene target | ND | DNA Sciences will use its high-throughput sequencing and genotyping facility to study the BMS gene in normal and affected disease populations (10/9) |
| ||||
DoubleTwist | NV Organon | Licensing agreement for the Prophecy database and tools suite, the Prophecy ToolKit and Genomatix Promoter Resource Database | ND | Prophecy will provide Organon access to DoubleTwist's annotated and assembled human genome database, as well as data mining and visualization tools (10/22) |
| ||||
Elitra Pharm- | Merck & Co. | Collaboration in which Elitra will provide antibiotic targets that Merck will screen against its natural product and compound libraries | ND | Elitra will receive an up-front payment and will get three years of research funding, as well as milestone payments and royalties (10/25) |
| ||||
First Genetic | GlaxoSmith- | Research collaboration to study genetic variations that influence why some patients experience certain adverse reactions when taking medications while others do not | ND | GlaxoSmithKline will conduct all analyses, while First Genetic Trust will provide secure genetic banking services, where biological samples and medical data can be stored (10/10) |
| ||||
Flamel Tech- | Merck & Co. | Licensing agreement for the application of Flamel's Micropump technology | ND | Merck will apply the technology to an undisclosed class of pharmaceutical compounds (10/10) |
| ||||
Galapagos | Pharmacia | Functional genomics collaboration involving the use of Galapagos' PhenoSelect expression platform for gene target identification and validation applications | ND | Galapagos will construct a gene library for Pharmacia to identify and validate drug targets in a broad range of disease areas (11/14) |
| ||||
Galapagos | Procter & | Collaboration under which P&G will use Galapagos' adenovirus technology as a tool to validate the utility of genes as new drug targets | ND | Galapagos will supply P&G with adenoviral vectors containing human genes selected by P&GP (10/22) |
| ||||
Genaissance | Pfizer Inc. | Agreement to give Pfizer selected data from Genaissance's Hap Database | ND | The database is a collection of markers of gene variations, known as haplotypes (10/9) |
| ||||
Genencor | Dow Corning | Agreement to mesh each company's knowledge in biotechnology and silicon chemistry to create a Silicon Biotechnology platform | $35 | Dow will provide $12M up front, plus research funding and milestones, for a a total of about $35M (10/22) |
| ||||
Genicon | Genomics | Multiyear agreement to employ Genicon's Resonance Light Scattering technology for use in GNF's internal proteomic microarray research | ND | The two parties will collaborate to further develop and commercialize RLS technology in conjunction with GNF's proteomic microarray technologies for the discovery of new drugs and drug targets (11/1) |
| ||||
ImClone | Bristol-Myers | Agreement to develop and promote IMC-225 | $2B | ImClone will receive $200M at the signing of the deal, $300M when the BLA for IMC-225 is completed and submitted, and $500M upon FDA approval of the drug; Bristol-Myers also will buy about 14.4M shares of ImClone, for another $1B (9/19) |
| ||||
Immusol Inc.* | Novartis | Five-year collaboration in which Immusol will deliver at least 50 targets to Novartis in the oncology area | $150 | Immusol will use its Inverse Genomics technology to discover the targets; Novartis will then develop compounds; the deal is valued at $150M (10/1) |
| ||||
Inhale Thera- | R.W. Johnson | Collaboration in which Inhale will use Inhance pulmonary delivery technology to develop formulations of inhaleable small-molecule compounds up to proof of concept | ND | R.W. Johnson and Janssen will evaluate and develop tested formulas; Inhale will receive research and development funding, milestone payments and royalty payments (10/10) |
| ||||
InterMune | Eli Lilly & | Exclusive, worldwide rights agreement to develop, manufacture and commercialize oritavancin | $50 | Lilly will receive $50M up front, as well as potential milestones and royalties on commercialized products; InterMune gets exclusive worldwide rights to develop, manufacture and commercialize oritavancin (9/20) |
| ||||
Invitrogen | American | Collaborative research service agreement for clones of genes | ND | Invitrogen will use its cDNA library and high-throughput gene isolation capabilities to provide full-length clones of genes targeted by Wyeth-Ayerst Laboratories (9/25) |
| ||||
Jerini AG | Aventis Pharma | Product development and licensing agreement for the compound Icatibant | ND | Jerini gains exclusive, worldwide, royalty-bearing rights to develop Icabitant in human health treatment (11/13) |
| ||||
Kosan | Meiji Seika | Research collaboration for Kosan's production of a polyketide in one of its hosts, and Kosan's development of a Meiji bacterium that produces a polyketide | ND | Meiji will provide funding for the one-year agreement (10/16) |
| ||||
Labopharm | Aventis Pharm- | Global licensing agreement to incorporate Labopharm's controlled-release technology, Contramid, into Allegra | ND | Labopharm will receive milestone payments and will earn royalties on product sales of the new formulations (11/14) |
| ||||
Lexicon | Pfizer Inc. | Nonexclusive internal research licensing agreement | ND | Agreement for a patent covering the use of Lexicon's isogenic DNA technology in gene targeting (10/10) |
| ||||
Lexicon Pharm- | Pfizer Inc. | Agreement for nonexclusive use to a library of chemical compounds | ND | Pfizer will use the compounds in its internal drug discovery programs (9/26) |
| ||||
LifeSpan | Aventis Pharma | Agreement for access to a LifeSpan database | ND | Aventis became the sixth subscriber to LifeSpan's database on expression and localization of G protein-coupled receptors (10/9) |
| ||||
LifeSpan | Wyeth-Ayerst | Subscription agreement for LifeSpan's G protein- coupled receptor database | ND | Wyeth-Ayerst gains access to the database (11/13) |
| ||||
Maxygen Inc. | Aventis Pasteur | Three-year agreement to develop improved vaccines for a specific target | $60 | Maxygen gets license fees, full research and development funding, minimum annual royalties, and potential milestone and royalty payments on product sales (11/5) |
| ||||
MediChem | Pharmacia | Two-year medicinal chemistry agreement | ND | MediChem will commit resources for drug discovery in collaboration with Pharmacia's in-house researchers; MediChem will be paid for its research and will receive royalties on resulting products (10/9) |
| ||||
Morphotek | Wyeth-Ayerst | Collaborative research agreement to develop cell lines | ND | Morphotek will apply its Direct-Line technology for the development of cell lines for Wyeth's internal research and development programs in oncology (9/27) |
| ||||
Myriad | Pharmacia | Collaboration on a research project in pharmacogenomics | ND | The project is aimed at identifying genetic differences among individuals in the general population (10/30) |
| ||||
Nastech Pharm- | G. Pohl | Exclusive licensing agreement for development and European commercialization rights to Nastech's intranasal morphine for treatment of moderate to severe pain | ND | Nastech will receive an up-front licensing fee, milestone payments and double-digit royalties for achieving certain goals (9/26) |
| ||||
NeoOncoRx | Bristol-Myers | Agreement to develop Elsamitrucin, which induces single-strand DNA breaks | ND | NeoOncoRx gains worldwide rights to develop and market the product (11/5) |
Novelos | HealthCare | Collaboration under which HealthCare Asia will develop and commercialize BAM-205 | ND | BAM-205 will be developed to treat hepatitis B and C in China (10/23) |
Orchid Bio- | GlaxoSmith- | Agreement to collaborate on a genome-wide validation of single nucleotide polymorphisms for pharmacogenetic studies | ND | Orchid will develop SNP assays and will conduct ultra-high-throughput genotyping analyses; GlaxoSmithKline will select SNP candidates from Orchid's design database (11/14) |
Paladin Labs | Novartis | Rogitine | ND | Paladin acquired the Canadian rights to Rogitine, which is indicated to prevent and control hypertensive episodes in patients with pheochromocytoma (11/7) |
Palatin Tech- | Serono Pharma- | Agreement in which Palatin will use Midas technology to generate compounds in support of Serono's research programs | ND | Financial details were not disclosed (10/1) |
Pharmacopeia | Boehringer | Collaboration to provide Boehringer with tools to test compounds against an undisclosed target | ND | Pharmacopeia will provide assay development expertise, a multimillion-compound sample collection and ultra-high-throughput screening (10/2) |
Progenics | UR Labs Inc. | Agreement for the rights to the pain-related drug methylnaltrexone | ND | The drug is entering Phase II trials; financial terms were not disclosed (10/1) |
Rosetta Bio- | GlaxoSmith- | Licensing agreement for the Rosetta Resolver Software Development Kit version 2.0 | ND | The kit offers customers direct access to the system's open application program interfaces (10/8) |
Quark Biotech | AstraZeneca | Collaborative agreement focusing on a search for cancer drug targets using QBI's BiFar technology | ND | QBI is providing 100 genes/proteins to AstraZeneca, and they will validate those that are functional; AstraZeneca will have the right to select and license a certain number of target genes and proteins for development, and it will have exclusive worldwide rights to commercialize products generated from the collaboration (10/3) |
Sequitur | Procter & | Agreement giving P&G access to Sequitur's functional genomics technology | ND | Sequitur will perform biological screening and provide its antisense methods and compounds to P&G target validation studies (10/9) |
SomaLogic* | Mitsui & Co. | Collaboration to identify potential aptamer customers in Asia | ND | Mitsui gained Asian rights to sell aptamers for certain proteomics applications; Mitsui also made an equity investment in SomaLogic (11/6) |
Sunesis Pharm- | Chiesi Farm- | Research collaboration to discover and develop small molecules that inhibit a well-validated protein- protein target involved in immunological diseases | $22- | Sunesis will receive up-front payments, research and development milestones and royalty payments based on sales; Chiesi will have an exclusive option to an exclusive license to develop and market any resulting products in Europe and Latin America; deal could be worth between $22M and $30M (10/10) |
Targesome | Merck KGaA | Research and collaboration agreement in which the companies will evaluate the potential of combining Merck's small-molecule antiangiogenesis compounds with Targesome's nanoparticle technology | ND | The companies will look at the potential for the making of new drugs for cancer and macular degeneration; the companies may enter into a collaboration to develop any drugs that come out of the research phase (10/23) |
Tripos Inc. | AstraZeneca | Multiyear, multimillion- dollar agreement to provide the Sybyl suite of in silico drug discovery software technologies | ND | The relationship will enable searching of databases to locate possible drug candidates, perform virtual testing of candidates and guide scientists seeking to improve the effectiveness of the best candidates (9/20) |
Valentis Inc. | Pfizer Inc. | Nonexclusive license for Valentis' GeneSwitch gene regulation technology | ND | The license is for research purposes only (10/23) |
Vysis Inc. | Roche Diag- | Exclusive license agreement that will provide Vysis access to genetic markers | ND | The markers may allow for the unique identification of fetal cells in a maternal blood sample (9/25) |
Weston Medi- | Chugai Pharm- | Option and licensing agreement giving Chugai access to Weston's Intraject needle-free drug delivery technology for the administration of an undisclosed therapeutic product | ND | Weston will receive an up-front fee and milestone payments, as well as potential royalties (10/8) |
Wilex AG | Bayer AG | License, sublicense and option agreement with Bayer's diagnostics group to obtain certain rights under Bayer's MN patent portfolio | ND | Wilex receives certain intellectual property rights that protect its G250 antibody; Bayer also granted to Wilex option rights to develop certain other antibodies targeting the MN antigen, as well as certain diagnostic option rights (11/12) |
Xerion Pharma- | Byk Gulden | Target validation agreement | ND | Xerion will use its XCALIbur technology for analysis; Byk Gulden will provide target proteins important to diseases such as cancer and inflammation (10/26) |
| ||||
NOTES | ||||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | ||||
* Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the Nasdaq market. | ||||
** Denotes the date the item ran in BioWorld International. |
||||
ND = Not disclosed, reported and/or available |
||||
AMEX = American Stock Exchange; LSE = London Stock Exchange; TSE = Toronto Stock Exchange |